The findings, published in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, offer new insight into how delusional beliefs may emerge and persist. Delusions are among the most recognizable symptoms of psychotic disorders: they are strongly held beliefs that remain resistant to contradictory evidence and can produce profound distress, social withdrawal, disability, and danger. Yet the cognitive processes that transform ordinary uncertainty into false certainty remain poorly understood. The new research points to the way people estimate environmental instability as one possible piece of that puzzle.

In computational psychiatry, a volatility prior describes a person’s expectation that the rules governing the world are likely to change. Someone with a relatively low volatility prior may assume that a pattern will remain stable unless there is strong evidence to the contrary. Someone with a high volatility prior, by contrast, may anticipate sudden shifts and treat the environment as unreliable, chaotic, or difficult to predict. Such expectations can influence how rapidly the brain updates its beliefs when new information arrives. When a person expects constant change, ambiguous events may be given disproportionate weight, potentially encouraging interpretations that become increasingly detached from external evidence.

Julia M. Sheffield, PhD, of Vanderbilt University Medical Center’s Department of Psychiatry and Behavioral Sciences, led the investigation to determine whether elevated volatility priors are a temporary feature of acute psychosis or a stable characteristic of people vulnerable to delusions. The distinction is clinically important. If volatility priors remain consistently high regardless of symptoms, they could represent a trait-like risk factor and a possible target for prevention. If they change alongside psychotic symptoms, they may instead function as a state marker—an indicator of the patient’s current clinical condition that could be influenced through treatment and recovery.

The research team recruited 75 adults with schizophrenia-spectrum disorders who had recently experienced an acute psychotic episode involving delusional thought content. Participants were assessed at six timepoints across six months, allowing investigators to track changes in cognition and symptoms rather than relying on a single snapshot. Their results were compared with data from 71 people without a diagnosed psychiatric disorder. To estimate volatility priors, participants completed a probabilistic reversal learning task, a behavioral experiment designed to measure how people respond when the relationship between choices and outcomes changes.

In this task, participants learn that one choice is more likely to produce a reward than another, but the probabilities periodically reverse. Successful performance requires tracking the environment, detecting when a pattern has changed, and adjusting behavior accordingly. The researchers used computational modeling to separate different components of decision-making, including how strongly participants expected the environment to shift. This approach does not directly measure a belief such as “the world is dangerous” or “people are plotting against me.” Instead, it estimates a more basic parameter governing belief updating: how much unpredictability a person expects before new evidence is presented.

At the beginning of the study, participants with schizophrenia-spectrum disorders showed significantly higher volatility priors than the non-clinical comparison group. Their delusional thinking, paranoia, and volatility expectations remained elevated at the end of the six-month follow-up and did not fully return to control levels. Nevertheless, all three measures generally declined over time, and the longitudinal analyses revealed that reductions in volatility priors were associated with improvements in delusion severity and paranoia. The relationship was specific: volatility priors were not significantly linked to changes in depression or worry, suggesting that the computational signal may be more closely related to psychotic belief formation than to general emotional distress.

The association remained after researchers accounted for antipsychotic medication and baseline cognitive ability. That finding does not show that changes in volatility priors caused delusions to improve, nor does it establish that modifying these expectations would necessarily eliminate psychotic symptoms. However, it strengthens the case that volatility priors track an important dimension of psychosis beyond medication exposure or overall intellectual performance. The researchers also found some evidence that the relationship was stronger for paranoid or persecutory delusions, in which people believe they are being watched, targeted, threatened, or harmed by others. Such beliefs may be particularly sensitive to expectations that social environments are unstable and unpredictable.

Repeated testing introduced an important complication. Participants completed the same type of task six times, and practice can alter performance independently of any genuine change in cognition. People may become faster, more accurate, or more familiar with the structure of an experiment simply because they have seen it before. The investigators attempted to reduce and account for these practice effects, but they acknowledge that the study remains partly confounded by repeated exposure. At the same time, the continued elevation of volatility priors after six months and six task sessions provided some reassurance that participants were not merely over-learning the experiment. The modeling results appeared to retain sensitivity to individual differences in volatility expectations beyond simple task familiarity.

The study’s implications extend beyond measurement. Antipsychotic medications, which broadly influence dopamine signaling, remain a central treatment for psychotic disorders, but responses vary substantially and many patients continue to experience delusions. Cognitive behavioral therapy for psychosis and other psychological interventions might eventually use computational information about belief updating to help patients examine how they interpret uncertainty and how rapidly they revise conclusions. A future treatment could, in principle, focus on recalibrating expectations about instability, helping individuals distinguish genuine changes in their environment from ordinary fluctuations or ambiguous events. Such an approach would need to be tested rigorously in controlled clinical trials before it could be considered an established therapy.

Sheffield and colleagues describe their results as foundational evidence that volatility priors are elevated during psychosis, decline during recovery, and move in parallel with the severity of specific delusional experiences. The work does not suggest that people with schizophrenia-spectrum disorders simply misread reality because they expect everything to change, nor does it reduce delusions to a single computational mechanism. Psychosis is biologically and psychologically diverse, and several interacting processes—including dopamine function, attention, learning, memory, social reasoning, and prior experiences—are likely to shape symptoms. Even so, identifying a measurable process that changes with recovery could help researchers connect laboratory models of belief updating with clinical treatment. The ultimate goal is to translate that connection into more precise and effective ways to reduce the disabling burden of delusions for patients and their families.

Subject of Research: People

Article Title: Longitudinal Associations Between Volatility Priors and Delusions in Individuals Recovering from an Acute Psychotic Episode

News Publication Date: August 18, 2026

Web References: https://doi.org/10.1016/j.bpsc.2026.06.013; Biological Psychiatry: Cognitive Neuroscience and Neuroimaging: https://www.sobp.org/bpcnni

References: Sheffield JM et al., “Longitudinal Associations Between Volatility Priors and Delusions in Individuals Recovering from an Acute Psychotic Episode,” Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, published July 3, 2026. DOI: 10.1016/j.bpsc.2026.06.013

Keywords: schizophrenia-spectrum disorders, delusions, psychosis, paranoia, volatility priors, computational psychiatry, belief updating, probabilistic reversal learning, cognitive markers, psychiatric treatment

Long-acting injectable antipsychotics, often known as LAIs, are formulations administered at regular intervals rather than taken as tablets every day. Depending on the medication, injections may be given every few weeks or months. Their main pharmacological advantage is the creation of a more stable drug concentration in the bloodstream, reducing the peaks and troughs that can occur with irregular oral dosing. This steady exposure may help prevent symptom recurrence, while scheduled appointments allow clinical teams to maintain regular contact with patients and identify early warning signs.

However, medication alone does not address every factor that influences recovery from schizophrenia. The disorder can affect memory, motivation, social communication, employment, relationships and the ability to organize daily activities. Psychosocial interventions are designed to target these difficulties directly. They may include psychoeducation, cognitive-behavioural approaches, family-focused work, skills training, supported employment, social rehabilitation and strategies for recognizing relapse. In an evidence-based model, these interventions are selected because previous research has shown that they can improve specific clinical or functional outcomes.

The new study is important because it examines this combined approach in routine psychiatric services rather than only in highly controlled research settings. Its prospective, multicenter design means that participants were followed forward in time across more than one clinical site, allowing investigators to observe treatment as it unfolded in the real world. Such studies can capture the complexity of ordinary care, including differences in clinical resources, patient preferences, family involvement and the practical challenges of attending appointments.

The phrase “recent-onset schizophrenia” refers to an early stage of the illness, when treatment decisions may have consequences lasting for years. Although some patients experience substantial recovery after the first episode, others develop persistent symptoms or repeated relapses. Each relapse can disrupt education, work, housing and social relationships, and may be associated with a more difficult recovery trajectory. Early intervention therefore aims not only to reduce hallucinations and delusions, but also to protect cognition, independence and participation in everyday life.

Combining an LAI with psychosocial care may address two different mechanisms of treatment failure. The injectable medication can reduce the risk that symptoms return because doses are missed, while psychosocial support can improve the patient’s ability to understand the illness, manage stress and engage with treatment. Family interventions may also help relatives distinguish early signs of relapse from ordinary fluctuations in mood or behaviour. From a systems perspective, this combination may turn each injection visit into part of a broader recovery plan rather than treating medication delivery as an isolated procedure.

A major scientific question is whether interventions proven effective in specialized trials retain their benefits when delivered across ordinary healthcare settings. Real-world treatment is affected by comorbid substance use, physical illness, socioeconomic disadvantage, stigma and inconsistent access to psychotherapy. Patients may also vary greatly in their willingness to receive an injection or participate in structured psychological programs. By studying these conditions prospectively and across multiple centers, the researchers aim to provide evidence that is more closely connected to the decisions faced by clinicians and health services.

The study also highlights a shift in how treatment success is defined. Controlling positive symptoms such as hallucinations and delusions remains essential, but modern schizophrenia care increasingly evaluates negative symptoms, cognitive performance, social functioning, quality of life and involvement in education or employment. These outcomes can change more slowly than acute symptoms and may require targeted rehabilitation. A patient who is clinically stable but isolated, unemployed and unable to manage daily responsibilities may still need intensive support, even when medication is effectively preventing psychosis.

The findings are likely to be relevant for mental-health services planning early-intervention programs. If evidence-based psychosocial interventions can be delivered consistently alongside LAIs, clinics may be able to create more durable treatment pathways for people at the beginning of schizophrenia. The approach could also support shared decision-making, because patients and families can discuss not only which medication is appropriate, but also which psychological, social and functional goals matter most. At the same time, the study’s real-world setting underscores that successful implementation depends on trained professionals, continuity of care and access to services beyond medication administration.

The research does not suggest that a single treatment formula will work for every person with recent-onset schizophrenia. Instead, it places the emphasis on combining pharmacological stability with personalized psychosocial recovery strategies. Its broader message is that early schizophrenia care should be measured by more than symptom reduction alone. The goal is to preserve the person’s ability to learn, work, maintain relationships and participate in society while reducing the risk of relapse. As psychiatric medicine continues to move toward integrated and recovery-oriented care, prospective evidence from everyday clinical practice may help determine how these ambitious goals can be achieved at scale.

Subject of Research: Evidence-based psychosocial interventions combined with long-acting injectable antipsychotic treatment in recent-onset schizophrenia.

Article Title: Evidence-based psychosocial interventions in recent-onset schizophrenia treated with long-acting injectable antipsychotics: a real-world prospective multicenter study.

Article References: Vita, A., Nibbio, G., Corrivetti, G. et al. “Evidence-based psychosocial interventions in recent-onset schizophrenia treated with long-acting injectable antipsychotics: a real-world prospective multicenter study.” Schizophrenia (2026). https://doi.org/10.1038/s41537-026-00791-6

Image Credits: AI Generated

DOI: 10.1038/s41537-026-00791-6

Keywords: schizophrenia, recent-onset psychosis, long-acting injectable antipsychotics, psychosocial interventions, early intervention, real-world study, mental health, relapse prevention, recovery-oriented care

Social cognition deficits in schizophrenia encompass a spectrum of impairments, including difficulties with emotion recognition, theory of mind, social perception, and attributional style. These deficits not only predict poor functional outcomes but also resist conventional pharmacological and psychosocial interventions. While antipsychotic medications effectively reduce positive symptoms such as hallucinations and delusions, their impact on social cognition remains limited. The systematic review brings to the forefront neuromodulation as a novel, non-invasive approach capable of targeting neural circuits implicated in social cognitive processes.

Neuromodulation encompasses a variety of techniques designed to modulate neural activity directly, including transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), and deep brain stimulation (DBS). Each modality acts through distinct mechanisms to alter brain excitability and neuroplasticity. TMS uses magnetic pulses to induce electrical currents in specific cortical areas, potentially rebalancing dysfunctional networks. tDCS delivers weak electrical currents via scalp electrodes to modulate neuronal membrane potentials and synaptic efficacy subtly. DBS involves implanted electrodes sending electrical impulses to deep brain structures, used primarily in refractory cases due to its invasive nature.

The review systematically evaluated clinical trials and experimental studies encompassing these techniques to determine their effectiveness in enhancing social cognitive abilities in schizophrenia patients. The authors highlight that while research is still nascent, accumulating evidence points to the dorsolateral prefrontal cortex (DLPFC) and medial prefrontal cortex (mPFC) as critical targets due to their integral roles in social information processing and executive function. Neuromodulation aimed at these cortical regions has demonstrated improvements in emotion recognition, mentalizing, and social decision-making tasks in several controlled studies.

One pivotal aspect illuminated by the review is the interplay between neuromodulation-induced plasticity and cognitive remediation therapies. Combining neuromodulation with behavioral interventions appears to yield synergistic benefits, whereby neuromodulation primes neural circuits to become more receptive to training and rehabilitation. This suggests that personalized, multimodal treatment plans could address the stubborn social cognition deficits more effectively than monotherapy approaches. The authors underscore that optimizing stimulation parameters and timing relative to cognitive therapy sessions is a critical research frontier.

Moreover, the neurobiological mechanisms underpinning neuromodulation effects involve modulation of neurotransmitter systems, including glutamatergic and dopaminergic pathways implicated in schizophrenia. By enhancing cortical excitability and plasticity, neuromodulation may recalibrate aberrant connectivity patterns that disrupt social cognitive networks. This mechanistic understanding offers valuable insight into why these methods hold promise beyond symptom suppression—to potentially restore underlying neural circuit function.

Despite the promising outcomes, the review also calls attention to the heterogeneity of study designs, small sample sizes, and variability in outcomes reporting across the neuromodulation literature. This methodological inconsistency hampers definitive conclusions and highlights the urgent need for large-scale, rigorously controlled trials. Such studies would clarify optimal stimulation targets, dosages, and patient selection criteria, ultimately facilitating translation into clinical practice. Importantly, safety profiles and long-term effects warrant continued monitoring, although current evidence suggests neuromodulation is generally well-tolerated.

Furthermore, neuromodulation offers unprecedented opportunities to explore brain-behavior relationships in schizophrenia through experimental manipulation of discrete circuits. This bidirectional research can inform both mechanistic theories of social cognition deficits and refinement of therapeutic strategies. The review proposes integration with neuroimaging and electrophysiological biomarkers to personalize interventions and objectively track clinical responses, ushering in an era of precision psychiatry.

The societal implications of enhancing social functioning in schizophrenia cannot be overstated. Improved social cognition directly correlates with better community integration, employment prospects, and quality of life for affected individuals. By targeting these deficits with novel neuromodulatory therapies, clinicians can hope to mitigate the profound isolation and stigma typically encountered by patients. As the reviewed evidence accumulates, neuromodulation stands out as a beacon of hope aiming at the very core of schizophrenia’s most disabling aspects.

In addition to clinical applications, the review speculates on future technological advancements that may further potentiate neuromodulation efficacy, such as closed-loop systems responsive to real-time neural activity and hybrid devices combining stimulation with cognitive feedback. These innovations could enable dynamic, adaptive interventions that maximize therapeutic gain and minimize side effects. The field stands on the cusp of integrating artificial intelligence and machine learning tools to tailor interventions uniquely to individual neural and behavioral phenotypes.

Overall, Neves, Ventura, and Madeira’s systematic review not only synthesizes current evidence but also charts critical pathways for future investigation into neuromodulation as a transformative treatment for social cognition dysfunction in schizophrenia. It highlights a shift from solely symptomatic management toward circuit-based remediation, emphasizing the plasticity of the social brain and the extraordinary potential to harness it therapeutically. For researchers, clinicians, and patients alike, these insights portend a more hopeful future in addressing one of psychiatry’s most daunting challenges.

As neuromodulation devices become more accessible and user-friendly, there is potential for broader integration into routine schizophrenia care, including home-based treatments under clinical supervision. Additionally, ethical considerations surrounding patient autonomy, informed consent, and equitable access will be paramount as these technologies evolve from experimental to standard care. Engaging diverse stakeholders will ensure responsible and socially just implementation.

This systematic review underscores the fundamental importance of interdisciplinary collaboration across psychiatry, neuroscience, engineering, and rehabilitation sciences to refine neuromodulation protocols. Through such concerted efforts, it is conceivable that the decades-long struggle against social cognition deficits in schizophrenia will at last yield to innovation, transforming lives and dismantling barriers once thought insurmountable.

In conclusion, neuromodulation emerges from this comprehensive review as a promising, mechanistically grounded modality for restoring social cognitive function in schizophrenia. While further research is essential to optimize efficacy and safety, current findings provide a compelling justification for expanded clinical trials and integration into multimodal treatment frameworks. The ongoing advancements in this field truly exemplify the convergence of technological ingenuity and clinical necessity, opening new horizons in the quest to ameliorate the social suffering intrinsic to schizophrenia.

Subject of Research: Neuromodulation as a treatment for social cognition dysfunction in schizophrenia.

Article Title: Neuromodulation in the treatment of social cognition dysfunction in Schizophrenia: a systematic review.

Article References:
Neves, M.M., Ventura, F. & Madeira, N. Neuromodulation in the treatment of social cognition dysfunction in Schizophrenia: a systematic review. Schizophr 11, 87 (2025). https://doi.org/10.1038/s41537-025-00629-7

Image Credits: AI Generated